Kovaltry logo

Welcome to the Kovaltry
healthcare professional section

Kovaltry (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for:1

  • Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes
  • Control and prevention of episodic bleeding
  • Peri-operative management (surgical prophylaxis)

 

Kovaltry does not contain von Willebrand factor and is not indicated for the treatment of von Willebrand disease.

 

Click here for additional safety information and a link to the product monograph discussing:1

  • Contraindications in patients who are hypersensitive to Kovaltry or to any ingredient in the formulation or component of the container, or with a known hypersensitivity to mouse or hamster protein
  • Most serious warnings and precautions regarding the development of circulating neutralizing antibodies
  • Other relevant warnings and precautions regarding percutaneous puncture with a needle contaminated with blood transmitting infectious viruses including HIV (AIDS) and hepatitis, hypersensitivity reactions, including anaphylaxis, pregnant and nursing women, and monitoring and laboratory tests related to the development of inhibitors and the clinical effect of Kovaltry
  • Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

 

Click on the option below to learn more.

What is Kovaltry?

Dosing information

Pharmacokinetics

Efficacy profile

Manufacturing

Safety profile

Storage

Important safety information

Summary